MEHLMAN CONSULTING, INC. for MAYO CLINIC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
General healthcare; health reform; healthcare value and quality; health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability. Promoting biomedical research. Opioid addiction and treatment. S. 1895: Lower Health Care Costs Act. Patent issues impacting clinical laboratory innovation. Clinical laboratory capacity and reimbursement issues. Financial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19. H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123 H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127 H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN ARONSON | — |
| MCKENZIE BRICE | — |
| DAVID CASTAGNETTI | — |
| NICHOLE DISTEFANO | — |
| SAGE EASTMAN | — |
| ELISE FINLEY PICKERING | — |
| STEVE HARO | — |
| CONSTANTINE HINGSON | — |
| BRUCE MEHLMAN | — |
| MICHAEL ROBINSON | — |
| DEAN ROSEN | — |
| DAVID R THOMAS | — |
| PAUL THORNELL | — |
| HELEN TOLAR | — |
Veterans VET
Reimbursement issues. Meetings with Members of Congress regarding Mayos role in supporting VAs efforts to modernize agreements with community providers of care to veterans.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN ARONSON | — |
| MCKENZIE BRICE | — |
| DAVID CASTAGNETTI | — |
| NICHOLE DISTEFANO | — |
| SAGE EASTMAN | — |
| ELISE FINLEY PICKERING | — |
| STEVE HARO | — |
| CONSTANTINE HINGSON | — |
| BRUCE MEHLMAN | — |
| MICHAEL ROBINSON | — |
| DEAN ROSEN | — |
| DAVID R THOMAS | — |
| PAUL THORNELL | — |
| HELEN TOLAR | — |
Medicare/Medicaid MMM
General healthcare; health reform; healthcare value and quality; health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability. Promoting biomedical research. Opioid addiction and treatment. Rural health. Clinical laboratory capacity and reimbursement issues. Financial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN ARONSON | — |
| MCKENZIE BRICE | — |
| DAVID CASTAGNETTI | — |
| NICHOLE DISTEFANO | — |
| SAGE EASTMAN | — |
| ELISE FINLEY PICKERING | — |
| STEVE HARO | — |
| CONSTANTINE HINGSON | — |
| BRUCE MEHLMAN | — |
| MICHAEL ROBINSON | — |
| DEAN ROSEN | — |
| DAVID R THOMAS | — |
| PAUL THORNELL | — |
| HELEN TOLAR | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.